Coalition to Cure Calpain 3 requests applications for research and translational projects related to calpain 3 and limb-girdle muscular dystrophy type 2A (LGMD2A, also called LGMDR1 Calpain 3-related). The goal of the RFA is to enable the development of therapeutic approaches for this disease. This opportunity is open to investigators from both US and non-US based academic and biopharmaceutical organizations. Letters of Intent are due by September 1, 2021, with full applications due by November 1, 2021.

The RFA can be found here.

FUNDING OPPORTUNITY! Coalition to Cure Calpain 3 Issues Request for Applications for Research Related to LGMD2A/R1
Tagged on: